158 related articles for article (PubMed ID: 23733227)
1. Avidity of onconeural antibodies is of clinical relevance.
Totland C; Ying M; Haugen M; Mazengia K; Storstein A; Aarseth J; Martinez A; Vedeler C
Cancer Immunol Immunother; 2013 Aug; 62(8):1393-6. PubMed ID: 23733227
[TBL] [Abstract][Full Text] [Related]
2. Hu and Yo antibodies have heterogeneous avidity.
Totland C; Aarseth J; Vedeler C
J Neuroimmunol; 2007 Apr; 185(1-2):162-7. PubMed ID: 17336396
[TBL] [Abstract][Full Text] [Related]
3. Onconeural antibodies in sera from patients with various types of tumours.
Monstad SE; Knudsen A; Salvesen HB; Aarseth JH; Vedeler CA
Cancer Immunol Immunother; 2009 Nov; 58(11):1795-800. PubMed ID: 19294382
[TBL] [Abstract][Full Text] [Related]
4. Onconeural antibodies: improved detection and clinical correlations.
Storstein A; Monstad SE; Haugen M; Mazengia K; Veltman D; Lohndal E; Aarseth J; Vedeler C
J Neuroimmunol; 2011 Mar; 232(1-2):166-70. PubMed ID: 21093932
[TBL] [Abstract][Full Text] [Related]
5. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
[TBL] [Abstract][Full Text] [Related]
6. Multiplex serology of paraneoplastic antineuronal antibodies.
Maat P; Brouwer E; Hulsenboom E; VanDuijn M; Schreurs MW; Hooijkaas H; Smitt PA
J Immunol Methods; 2013 May; 391(1-2):125-32. PubMed ID: 23500780
[TBL] [Abstract][Full Text] [Related]
7. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
Seluk L; Taliansky A; Yonath H; Gilburd B; Amital H; Shoenfeld Y; Kivity S
Clin Immunol; 2019 Feb; 199():29-36. PubMed ID: 30543927
[TBL] [Abstract][Full Text] [Related]
8. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
9. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Honnorat J; Cartalat-Carel S; Ricard D; Camdessanche JP; Carpentier AF; Rogemond V; Chapuis F; Aguera M; Decullier E; Duchemin AM; Graus F; Antoine JC
J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):412-6. PubMed ID: 18931014
[TBL] [Abstract][Full Text] [Related]
10. Which antibody and which cancer in which paraneoplastic syndromes?
Gozzard P; Maddison P
Pract Neurol; 2010 Oct; 10(5):260-70. PubMed ID: 20858627
[TBL] [Abstract][Full Text] [Related]
11. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
Monstad SE; Storstein A; Dørum A; Knudsen A; Lønning PE; Salvesen HB; Aarseth JH; Vedeler CA
Clin Exp Immunol; 2006 Apr; 144(1):53-8. PubMed ID: 16542365
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease.
Qvale TH; Storstein A; Mazengia K; Eagan TM; Bakke PS; Vedeler CA
Respirology; 2014 Jul; 19(5):730-4. PubMed ID: 24697843
[TBL] [Abstract][Full Text] [Related]
14. Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).
Totland C; Bredholt G; Haugen M; Haukanes BI; Vedeler CA
Cancer Immunol Immunother; 2010 Feb; 59(2):231-7. PubMed ID: 19680650
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
16. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique.
Knudsen A; Monstad SE; Dørum A; Lønning PE; Salvesen HB; Drivsholm L; Aarseth JH; Vedeler CA
Cancer Immunol Immunother; 2006 Oct; 55(10):1280-4. PubMed ID: 16429314
[TBL] [Abstract][Full Text] [Related]
17. Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.
Lower EE; Sturdivant M; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):254-260. PubMed ID: 32476961
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
[TBL] [Abstract][Full Text] [Related]
19. CRMP5 antibodies in patients with small-cell lung cancer or thymoma.
Monstad SE; Drivsholm L; Skeie GO; Aarseth JH; Vedeler CA
Cancer Immunol Immunother; 2008 Feb; 57(2):227-32. PubMed ID: 17657489
[TBL] [Abstract][Full Text] [Related]
20. The Positive Predictive Value of Onconeural Antibody Testing: A Retrospective Review.
Budhram A; Nicolle MW; Yang L
Can J Neurol Sci; 2018 Sep; 45(5):577-579. PubMed ID: 30234468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
